Group items matching

in title, tags, annotations or url

Ensuring comprehensive healthcare services for the community necessitates collaboration between pharmacies and GP surgeries. However, several pharmacists have voiced concerns about a lack of cooperation from their local GPs in implementing the Pharmacy First (PF) service. In a survey conducted by the National Pharmacy Association (NPA) covering 470 pharmacies across England, three-quarters of pharmacists (77 per cent) indicated that local GP practices are not appropriately referring patients to the new service. The survey highlighted instances of patients either not being referred or being referred but found ineligible for support through Pharmacy First. Additionally, one in five NPA members (19 per cent) felt that their local GP practices were not engaging with the initiative at all. Commenting on the issue, NPA chair Nick Kaye said: "Feedback from across our network suggests that the rollout of Pharmacy First varies considerably from area to area.

Walgreens Boots Alliance (WBA) has officially announced that Sebastian James, the Managing Director of Boots, will be stepping down from his role to pursue a new opportunity in the healthcare sector. James has given notice to leave the company and will remain with Boots until November. The UK pharmacy giant has already begun the search for a new Managing Director. James is set to take on the role of CEO at Veonet, a leading European chain of ophthalmology clinics. During his tenure as Managing Director since 2018, James played a pivotal role in transforming Boots into the UK's leading health and beauty retailer. He oversaw significant growth and innovation, achieving thirteen consecutive quarters of retail market share growth. Most recently, the company announced strong Q3 results in June with growth across all categories.

The National Health Service(NHS) has reported a record number of attendances at Accident & Emergency (A&E) departments and emergency admissions for any June, reflecting significant pressure on healthcare services amidst hot weather and recent strikes by junior doctors. Last month, hospitals across the UK handled over 2.29 million A&E attendances and more than 536,884 emergency admissions, marking increases of 3.1 per cent and 7.2 per cent respectively compared to the previous year. Professor Sir Stephen Powis, NHS national medical director, acknowledged the strain on frontline teams: "Frontline teams are continuing to work exceptionally hard under significant pressure to provide the best care they can for patients."

The Royal Pharmaceutical Society (RPS) Director for Scotland Clare Morrison participated in the panel discussion alongside representatives from other health professional organisations on tackling the workforce crisis at the SNP conference in Aberdeen on 8 October. At the conference, the Cabinet Secretary for Health and Social Care committed to achieving protected learning time for health professionals. Morrison welcomed the Cabinet Secretary's statement as fantastic news for pharmacists across Scotland. "RPS Scotland will follow up the discussion by writing to the Cabinet Secretary to request a meeting to discuss achieving protected learning time, the forthcoming results of our workforce wellbeing survey, and positive examples of how pharmacy teams have improved the well-being of their teams," said the society.

The Medicines and Healthcare products Regulatory (MHRA) and Genomics England to launch a brand-new genetic research resource, known as a 'biobank' on Thursday (June 01) to tackle the issue of Adverse Drug Reactions (ADRs). Biobank will help to better understand how a patient's genetic makeup can impact the safety of their medicines. "The Yellow Card biobank, which will contain genetic data and patient samples, will operate alongside the MHRA's Yellow Card reporting site for suspected side effects and adverse incidents involving medicines and medical devices," said MHRA. The biobank pilot will officially begin on 1 June 2023 with participant recruitment commencing later this year, on 1 September. The sequencing of participants' genetic material will begin in Spring 2024, with initial research findings from the pilot due to be published in 2025. Genomics England will be supporting the MHRA with sequencing and storage of genetic material through use of their well-established and secure infrastructure.

The Pharmaceutical Services Negotiating Committee (PSNC)'s 2022 Pharmacy Advice Audit revealed that more than 1.2 million consultations a week - or 65 million a year - are now being carried out by community pharmacy teams in England. This is an increase from 2021, when the audit results suggested that in total pharmacies were providing 58 million consultations per year. PSNC has published the findings of the audit of over 4,000 community pharmacies carried out earlier this year. During the audit, 82,872 informal patient consultations were recorded, with the average pharmacy completing 19 consultations per day. This suggests that more than 1.2 million informal consultations are taking place in community pharmacies in England every week. The audit helped to quantify the number of informal referrals being made to pharmacies by GPs and NHS 111, with 7,774 informal patient referrals into pharmacy coming from these routes; grossed up to a national level that means 117,000 cases per week. These are all referrals that could and should have been made by the NHS Community Pharmacist Consultation Service (CPCS).

National pharmacy bodies have called on the government and NHS leaders to take appropriate action to keep pharmacy teams safe from violence and abuse. The Pharmaceutical Services Negotiating Committee (PSNC) - in collaboration with the Association of Independent Multiple Pharmacies (AIMp), the Company Chemists' Association (CCA), the National Pharmacy Association (NPA), and the Royal Pharmaceutical Society (RPS) - is supporting an important petition started by Mike Hewitson, a community pharmacy contractor, who has been threatened with stabbing and robbed in his own pharmacy. The PSNC and the other national pharmacy bodies strongly believe that no healthcare professional should have to deal with this, that and pharmacists and their teams should be better protected. It said: "Community pharmacies play an integral role in the delivery of primary care and most patients are highly appreciative of the hard work of local pharmacists and pharmacy teams from dispensing medicines and administering vaccines to providing medical advice and health monitoring services.

The chief pharmaceutical officer (CPhO) for Wales and chief pharmacists at Boots and the Ministry of Defence are among a total of 1,134 people who received an award in the Queen's Birthday Honours list to mark her Platinum Jubilee. All three pharmacists were appointed officers of the Order of the British Empire or OBE. Andrew Evans, CPhO for Wales, was honoured "for services to the Covid-19 Response", Marc Donovan, chief pharmacist at Boots UK, "for services to pharmacy" and Sumeet Kaur Matharu, chief pharmacist at the Ministry of Defence, "for services to Armed Forces Healthcare". Giving his reaction to Pharmacy Business, Donovan said: I'm honoured to accept this recognition on behalf of the many dedicated and hard-working pharmacists and pharmacy teams that I have had the privilege to work alongside over the years.

Sun Pharmaceutical Industries, India's largest drugmaker by revenue, reported a better-than-expected 5.2 per cent rise in third-quarter profit on Tuesday, driven by higher sales of its specialty drugs. The company, known for its consumer healthcare products such as Revital vitamins and pain relief medicine Volini, said it earned a consolidated net profit of 21.66 billion rupees ($265.23 million) in three months ended Dec. 31, up from 20.59 billion rupees last year. Analysts, on average, had expected the company to report a profit of 21.26 billion rupees, according to Refinitiv IBES data. Total revenue from operations climbed nearly 14 per cent to 112.41 billion rupees. Input costs rose 8.5 per cent. Drug sales in India rose 7.1 per cent to 33.92 billion rupees, whereas sales in the United States climbed 16.6 per cent to 34.66 billion rupees, with each of the two regions accounting for 31 per cent of the company's total consolidated sales. The company, founded in 1983, makes over-the-counter medications, anti-retrovirals and active pharmaceutical ingredients for chronic and acute treatments.

In what's seen as a major step forward for the treatment of schizophrenia, the Medicines and Healthcare Products Regulatory Agency (MHRA) has authorised a new Johnson & Johnson drug in Britain. Byannli is a six-monthly paliperidone palmitate (PP6M) and is the first long-acting injectable schizophrenia treatment which offers patients the potential for up to six months of symptom control and a reduction in their risk of relapse with only two doses a year. It is a long-acting injectable that works by dissolving and entering the bloodstream slowly, due to its extremely low water solubility, resulting in continuous absorption of paliperidone palmitate over a six-month period. "Schizophrenia is a chronic and severe brain disorder, and antipsychotic medication plays an important role in its treatment. However, many people with the illness experience relapses which are often caused by poor adherence to oral medication," said Prof David Taylor, director of Pharmacy and Pathology at the Maudsley Hospital.

The International Pharmaceutical Federation (FIP) has issued a new policy statement which encourages a "life-course" approach to vaccination by pharmacists. In the statement, published on September 27, FIP backed expansion of vaccine schedules and strategies so that patients of all age groups could be vaccinated throughout their entire lifespan, from infancy to old age. A life-course approach in public health and healthcare focuses on an individual's health and well-being, including vaccination, administered throughout their entire lifespan, from infancy to old age. FIP urged governments and policymakers to eliminate regulatory barriers, enabling pharmacists to prescribe and administer all relevant vaccines throughout the life-course. Additionally, FIP recommended that policymakers develop remuneration models for pharmacies to deliver sustainable life-course vaccination services within the private and public sectors.

Thorrun Govind's journey in pharmacy is deeply influenced by her South Asian heritage, with a Punjabi mother and a Gujarati father shaping her professional path. She reflects on this influence: "I think my heritage has influenced my journey to become a pharmacist because there are a number of well-known and recognized figures in pharmacy who come from a South Asian background." "I think there's a tradition of hard work in my heritage. Additionally, many businesspeople in the community have also been a key influence. This entrepreneurial aspect has influenced my desire to pursue a career in pharmacy. It was always something I saw as part of my identity." Currently, Thorrun practices as both a pharmacist and a healthcare lawyer. She provides legal support to fellow pharmacists, including assistance with fitness to practice proceedings and business transactions. In June 2024, Thorrun joined Brabners' regulatory & professional conduct team, further expanding her role in the sector. Her journey, however, has not been without its challenges.

"It is crucial that patients can access care when they need it, whether from a pharmacist or a GP, " Paul Rees, Chief Executive of the National Pharmacy Association (NPA) has said. In response to a recent survey conducted by the General Medical Council (GMC) highlighting alarming trends among General Practitioners (GPs), the NPA has issued a warning about the growing crisis in the UK's primary care system. Rees emphasised the urgent need for government intervention, saying, "Only by reversing these cuts and providing pharmacies with a new funding deal will we be able to end the 8am scramble for appointments." The GMC survey reveals that there is a significant increase in the number of doctors reducing their working hours to safeguard their wellbeing, spotlighting concerns about the long-term impact on patient care. According to the report, nearly half of GPs ( 48 per cent) are struggling to manage their workload, with several resorting to decreasing their hours or declining additional work to protect their mental and physical health.

Prostate cancer is the most common cancer among men in the United Kingdom, affecting nearly 50,000 men yearly. Combined with the challenges faced across healthcare during COVID-19, new figures show that prostate cancer accounts for a third of cancers not treated due to the pandemic, with 14,000 'missing patients' believed to have not undergone treatment since April 2020. It is more urgent than ever that men are encouraged to get checked, as any set-backs in diagnosis can reduce the pathways available, in turn affecting health outcomes. Community pharmacy teams play a crucial role in signposting the help available for men who may be concerned about their health. Therefore, it is vital that pharmacy teams have access to the information they need to correctly direct men to seek prostate cancer guidance. By maximising the trusted relationship between patients and their pharmacists, more can be done to identify the warning signs, helping men to get an earlier diagnosis.

Approximately 25 million GP appointments and 5 million A&E visits are utilised each year for self-treatable illnesses. If these individuals chose to self-treat using over-the-counter (OTC) medications, the potential savings for NHS could amount to at least £1.7 billion annually, according to a research commissioned by Proprietary Association of Great Britain. The study, conducted by analysts at Frontier Economics, revealed that embracing self-care could bring an additional economic benefit of £350 million annually, as employees would avoid unnecessary time off from work for medical appointments. Apart from the savings resulting from the increased OTC medicine use, the report emphasises the potential benefits of reclassifying more prescription-only medications (POMs). A mere 5 per cent reduction in NHS prescribing levels and spending could lead to an annual cost-saving of £1.4 billion, encompassing both prescription costs and GP appointments, it said. "This substantial amount could greatly alleviate financial pressures on the NHS and offer essential resources for recruiting and training much-needed healthcare professionals."

The Department of Health and Social Care (DHSC) has published the full text of the 2024 voluntary scheme for branded medicines pricing, access and growth (VPAG). The 2024 VPAG agreement text sets out the detailed terms of the agreement reached between DHSC, NHS England and the Association of the British Pharmaceutical Industry (ABPI) to support patient access to medicines, the financial sustainability of the NHS and the UK life sciences sector. The new voluntary scheme will come into force on 1 January 2024, following expiry of the 2019 Voluntary Scheme and shall remain in force for a period of five years, until 31 December 2028. Manufacturers or suppliers of branded medicines to the NHS have been given time till 15 January 2024 to decide whether to join the new 2024 Voluntary Scheme, or default to the updated Statutory Scheme.

AAH Pharmaceuticals Ltd (AAH) has exceeded the milestone of delivering over 70 million COVID-19 vaccination doses across England, since it was awarded a contract in December 2020. In addition, AAH has delivered over 100 million ancillary items to more than 3,000 healthcare providers. David Bound, chief executive officer of AAH, said: "This is a huge milestone for AAH as we work tirelessly to support our communities. It's also a ringing endorsement of our delivery drivers, warehouse operatives, and specialist logistics teams and the determination, dedication, and passion they continue to show throughout this extraordinary period." The vaccination programme was also recognized by the Supply Chain Excellence Awards. Chris Emmott, senior project lead - Supply Chain, commented: "I'm incredibly proud that AAH was chosen for this job, particularly as we had the skills, the experience, and a great team to help facilitate the needs of the country. To get ready for a project like this, everybody's worked very long hours, they've worked weekends to get everything ready.

More than 1000 pharmacies in England, including Boots stores, are now delivering the newly launched NHS Pharmacy First Service. Launched on Wednesday (31 January), the new service enables pharmacists to provide advice and treatment, if appropriate, for seven common conditions, which include sinusitis, sore throat, earache, infected insect bite, impetigo, shingles, or an uncomplicated urinary tract infection in women. Instead of going to a GP surgery, patients can go to their community pharmacists to get treatment for these common conditions, without the need for an appointment. Patients who may need additional support will be referred to a GP or another healthcare provider by the pharmacist. Seb James, managing director of Boots UK and ROI, has described their launch of Pharmacy First service as "one of the most significant changes in how we can serve our customers and patients in our 175-year history."

The General Pharmaceutical Council (GPhC) has launched a new draft 'Equality Guidance' for pharmacies to tackle discrimination and make sure that everyone can access safe and effective person-centred pharmacy care. GPhC's consultation is seeking views on "the structure and language of the guidance, if anything is missing and the impacts on patients and members of the public, pharmacy staff, pharmacy owners, and individuals or groups sharing any of the protected characteristics." The regulator said the draft guidance is designed to support pharmacy owners to: demonstrate that they are meeting our standards for registered pharmacies fulfil their legal and regulatory duties in relation to equality help protect the rights of individuals advance equal opportunities for staff, patients and the wider public help improve the experience and healthcare outcomes of patients and members of the public.

The Royal Pharmaceutical Society (RPS) has published a new professional guidance for prescribing practice on Monday (June 6) which it says will be "for the benefit of all independent prescribers across the UK". Based on collaboration with multi-professional stakeholders, the document is a guidance tool for prescribers wanting to expand their prescribing scope of practice. Commissioned by the Welsh government, the document was developed through an expert group with representatives from many healthcare professions, including from Higher Education institutions, professional bodies, regulatory bodies, the National Institute for Health and Care Excellence, NHS Education for Scotland, Health Education and Improvement Wales, and representatives from hospital, community and GP practice. RPS president Claire Anderson said: "It's fantastic to see the growth in prescribing, both across the profession and more widely, to improve patient care.